Cash-strapped biotech flips ex-MedImmune anti-inflammatory drug for $15M cash
Having turned to layoffs earlier this year to tighten its financial belt, microcap biotech Avalo Therapeutics has now added some much-needed cash to the bank …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
